AADI BIOSCIENCE INC (AADI) Stock Price, Forecast & Analysis

NASDAQ:AADI • US00032Q1040

2.05 USD
-0.05 (-2.38%)
At close: Mar 18, 2025
2.06 USD
+0.01 (+0.49%)
After Hours: 3/18/2025, 8:20:08 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AADI Key Statistics, Chart & Performance

Key Statistics
Market Cap94.85M
Revenue(TTM)N/A
Net Income(TTM)-61.69M
Shares46.27M
Float43.33M
52 Week High3.81
52 Week Low1.21
Yearly Dividend0
Dividend YieldN/A
EPS(TTM)-2.35
PEN/A
Fwd PEN/A
Earnings (Next)05-06
IPO2018-06-26
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
AADI short term performance overview.The bars show the price performance of AADI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

AADI long term performance overview.The bars show the price performance of AADI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of AADI is 2.05 USD. In the past month the price decreased by -24.07%. In the past year, price decreased by -5.96%.

AADI BIOSCIENCE INC / AADI Daily stock chart

AADI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating
AADI Full Technical Analysis Report

AADI Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to AADI. While AADI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AADI Full Fundamental Analysis Report

AADI Financial Highlights

Over the last trailing twelve months AADI reported a non-GAAP Earnings per Share(EPS) of -2.35. The EPS increased by 3.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -71.98%
ROE -89.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-11.67%
Sales Q2Q%14.43%
EPS 1Y (TTM)3.69%
Revenue 1Y (TTM)N/A
AADI financials

AADI Forecast & Estimates

8 analysts have analysed AADI and the average price target is 3.06 USD. This implies a price increase of 49.27% is expected in the next year compared to the current price of 2.05.

For the next year, analysts expect an EPS growth of 71.14% and a revenue growth -46.53% for AADI


Analysts
Analysts47.5
Price Target3.06 (49.27%)
EPS Next Y71.14%
Revenue Next Year-46.53%
AADI Analyst EstimatesAADI Analyst Ratings

AADI Ownership

Ownership
Inst Owners61.01%
Ins Owners11.42%
Short Float %N/A
Short RatioN/A
AADI Ownership

AADI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.73403.74B
AMGN AMGEN INC16.99206.168B
GILD GILEAD SCIENCES INC16.55183.174B
VRTX VERTEX PHARMACEUTICALS INC23.91123.671B
REGN REGENERON PHARMACEUTICALS16.6281.636B
ALNY ALNYLAM PHARMACEUTICALS INC49.6943.973B
INSM INSMED INC N/A33.829B
NTRA NATERA INC N/A29.154B
BIIB BIOGEN INC12.8328.637B
UTHR UNITED THERAPEUTICS CORP16.0620.386B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About AADI

Company Profile

AADI logo image Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on applying technology to deliver improved precision oncology therapies for people living with difficult-to-treat cancers.

Company Info

AADI BIOSCIENCE INC

17383 Sunset Avenue, Suite A250

Pacific Palisades CALIFORNIA US

CEO: Joseph Gardner

Employees: 53

AADI Company Website

AADI Investor Relations

Phone: 14244738055

AADI BIOSCIENCE INC / AADI FAQ

What does AADI BIOSCIENCE INC do?

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on applying technology to deliver improved precision oncology therapies for people living with difficult-to-treat cancers.


What is the current price of AADI stock?

The current stock price of AADI is 2.05 USD. The price decreased by -2.38% in the last trading session.


Does AADI stock pay dividends?

AADI does not pay a dividend.


How is the ChartMill rating for AADI BIOSCIENCE INC?

AADI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How many employees does AADI BIOSCIENCE INC have?

AADI BIOSCIENCE INC (AADI) currently has 53 employees.


Can you provide the market cap for AADI BIOSCIENCE INC?

AADI BIOSCIENCE INC (AADI) has a market capitalization of 94.85M USD. This makes AADI a Micro Cap stock.


Can you provide the upcoming earnings date for AADI BIOSCIENCE INC?

AADI BIOSCIENCE INC (AADI) will report earnings on 2025-05-06, before the market open.